GlaxoSmithKline on Monday announced it would reduce the price of its Cervarix human papillomavirus (HPV) vaccine by 30 percent in Canada in a bid to boost immunisation rates. Effective immediately, the vaccine will cost 90 Canadian dollars ($87.63) per dose, with three doses recommended for optimal protection.
According to a recent survey, 9 out of 10 Canadian women aged 18 to 25 have not been vaccinated against HPV, with about half of those surveyed who do not have a private drug plan citing cost as a barrier to obtaining the vaccine. In addition, 61 percent of mothers of young women indicated that cost was a deterrent for immunisation.
Commenting on the new pricing model, Paul Lucas,CEO of GlaxoSmithKline Canada said "we've looked at the research and taken action to address the barrier where we were able to impact the most."
Reference Articles
GlaxoSmithKline drops the price of Cervarix - (GlaxoSmithKline)
Glaxo cuts Cervarix price by 30 pct in Canada - (London South East)
GlaxoSmithKline slashes cost of cervical cancer vaccine in Canada by 30% - (Proactive Investors)
**Published in "First Word"
No comments:
Post a Comment